Article Information
History
- July 22, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Shohei Yamamoto*,1,
- Ami Fukunaga*,1,
- Akihito Tanaka2,
- Junko S. Takeuchi3,
- Yosuke Inoue1,
- Moto Kimura3,
- Kenji Maeda4,
- Gohzoh Ueda5,
- Tetsuya Mizoue1,†,
- Mugen Ujiie6,
- Wataru Sugiura7 and
- Norio Ohmagari6
- 1Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Medicine, Tokyo Japan
- 2Department of Laboratory Testing, Center Hospital of the National Center for the Global Health and Medicine, Tokyo, Japan
- 3Department of Academic-Industrial Partnerships Promotion, Center for Clinical Sciences, National Center for Global Medicine, Tokyo Japan
- 4Department of Refractory Viral Infection, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan
- 5Division of Core Diagnostics, Abbott Japan LLC, Tokyo, Japan
- 6Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
- 7Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan
- ↵†Address for correspondence:
Tetsuya Mizoue, Department of Epidemiology and Prevention, National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan; email: mizoue{at}hosp.ncgm.go.jp
↵* Equal contribution as first author
Posted July 22, 2021.
Association between reactogenicity and SARS-CoV-2 antibodies after the second dose of the BNT162b2 COVID-19 vaccine
